Back to results
US 7,238,785 B2Granted
RS7 antibodies
AssigneeImmunomedics, Inc.
InventorsSerengulam Govindan, Zhengxing Qu, Hans Hansen, David Goldenberg
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeImmunomedics, Inc.
InventorsSerengulam Govindan, Zhengxing Qu, Hans Hansen, David Goldenberg
Estimating the term…
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
A humanized RS7 antibody or fragment thereof that binds to an EGP-1 glycoprotein, wherein the complementarity determining regions (CDRs) of the light chain variable region of the humanized RS7 antibody or fragment thereof comprise CDR1 comprising the amino acid sequence of KASQDVSIAVA (SEQ ID NO:28);
A humanized RS7 antibody or fragment thereof, wherein said humanized RS7 antibody or fragment thereof comprises the amino acid sequence encoded by the hRS7 Vκ nucleotide sequence (SEQ ID NO:11) and comprises the amino acid sequence encoded by the hRS7 VH nucleotide sequence (SEQ ID NO:13).
Dependencies are inferred from the claim text.